Recce Pharmaceuticals advances R327 Gel towards Phase 3 after promising Phase II trial
Recce Pharmaceuticals Limited has announced significant success in its Phase II trial of RECCE 327 topical gel (R327G), a synthetic anti-infective designed to treat acute ... Read More
Recce Pharmaceuticals secures phase II trial safety approval for breakthrough R327G treatment
Recce Pharmaceuticals Limited recently announced significant progress in its phase II clinical trial for RECCE 327 Topical Gel (R327G), an innovative treatment for acute bacterial ... Read More
Recce Pharmaceuticals completes cohort dosing in R327 Phase I/II trial
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) continues its trajectory in pioneering a new class of Synthetic Antiinfectives, spotlighting its recent achievement. The company announced that Scientia ... Read More